PQ Grass: A Long-Term Treatment for Seasonal Allergic Rhinitis in Children and Adolescents

What is PQ Grass?

PQ Grass, also known as Pollinex Quattro Grass, is a medication designed to treat seasonal allergies caused by grass pollen1. It contains a special ingredient called grass pollen allergen extract that has been modified with a substance called glutaraldehyde and attached to another substance called L-tyrosine1. This unique formulation is meant to help your body become less sensitive to grass pollen over time.

Medical Conditions Treated

PQ Grass is specifically designed to treat seasonal allergic rhinitis and rhinoconjunctivitis caused by grass pollen1. These conditions are more commonly known as "hay fever" and typically cause symptoms such as:

• Sneezing
• Runny or stuffy nose
• Itchy or watery eyes
• Itchy throat or ears

These symptoms usually occur during the grass pollen season, which can vary depending on your location but is often in late spring and early summer.

How PQ Grass Works

PQ Grass works through a process called immunotherapy. This means it helps train your immune system to be less reactive to grass pollen1. By exposing your body to small, controlled amounts of modified grass pollen allergens, PQ Grass aims to reduce your allergic symptoms over time. The L-tyrosine in the formula helps to slow down the release of the allergen, potentially making the treatment more effective and reducing side effects.

Clinical Trial Overview

A long-term clinical trial is being conducted to test the effectiveness and safety of PQ Grass in children and adolescents1. This trial is divided into two parts:

• Part A: A one-year study comparing PQ Grass to a placebo (a substance with no active medication)
• Part B: A five-year extension study to evaluate the long-term effects of PQ Grass

The trial is "double-blind," which means neither the participants nor the researchers know who is receiving PQ Grass and who is receiving the placebo during the study1. This helps ensure that the results are not influenced by expectations.

Eligibility Criteria

To participate in this clinical trial, children and adolescents must meet certain criteria1. Some key requirements include:

• Age: 5 to 16 years old
• History of moderate to severe seasonal allergic rhinitis due to grass pollen for at least one year
• Positive skin prick test to grass pollen
• Good general health

There are also several conditions that would prevent participation, such as severe asthma, certain autoimmune diseases, or allergies to other substances that might interfere with the study results1.

Treatment Administration

PQ Grass is given as a subcutaneous injection, which means it's injected just under the skin1. The treatment follows a specific schedule, starting with lower doses and gradually increasing to the full dose. This approach, known as dose escalation, helps reduce the risk of side effects.

Expected Benefits

The main goal of PQ Grass treatment is to reduce allergy symptoms during the grass pollen season. Researchers are measuring this using a Combined Symptom and Medication Score (CSMS)1. This score takes into account both how severe your symptoms are and how much allergy medication you need to use. The study is also looking at:

• Improvement in quality of life
• Changes in the immune system's response to grass pollen
• Long-term effectiveness of the treatment

Potential Side Effects

As with any medical treatment, PQ Grass may cause side effects. The clinical trial is carefully monitoring for any adverse events1. Common side effects of allergen immunotherapy can include:

• Redness, swelling, or itching at the injection site
• Mild allergy symptoms such as sneezing or itchy eyes
• In rare cases, more severe allergic reactions

The study includes safety measures to minimize risks and handle any reactions that might occur.

Long-Term Effects

One of the key goals of this study is to understand the long-term effects of PQ Grass treatment1. Researchers are looking at whether the benefits of treatment continue even after stopping the medication. This could potentially mean long-lasting relief from grass pollen allergies.

The study is also monitoring for any long-term changes in the immune system, particularly levels of an antibody called IgG4, which may indicate a positive response to the treatment1.